
CLAIMS

1. A compound having the chemical structure:



, in which:

- R_1 is independently selected from: -OR_{1a}-, -SR_{1a}-, -NR_{1a}-, -$NR_{1a}C(O)R_{1a}$-, -$OC(O)R_{1a}$-, -$C(O)OR_{1a}$-, -SO_2R_{1a}, -$S(O)R_{1a}$-, -$NR_{1a}C(O)$-, -$C(O)NR_{1a}$ -, -$NR_{1a}S(O)_2$-, $S(O)_2NR_{1a}$-, -$OC(O)NR_{1a}$-, -$NR_{1a}C(O)OR_{1a}$- , -$NR_{1a}C(O)NR_{1a}$-, -CR_{1a}=CR_{1a}-, -CC-, and -CH_2R_{1a}-;
- R_{1a} is independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl heterocycloalkyl, heteroaryl or phenyl is optionally substituted where chemically allowed by from 1 to 4 groups independently selected from oxo, C_1-C_{18}-alkyl, C_2-C_{18}-alkynyl, C_2-C_{18}-alkenyl, C_1-C_{18}-haloalkyl; OR_a, NR_aR_b, SR_a, $C(O)OR_a$, $C(O)NR_aR_b$, halo, cyano, nitro, $C(O)R_a$, and $S(O)_2OR_a$;
    - wherein R_a is independently at each occurrence selected from: H and C_1-C_{18}-alkyl; and R_b is independently at each occurrence selected from: H and C_1-C_{18}-alkyl, $C(O)C_1$-C_{18}-alkyl and $S(O)_2$-C_1-C_{18}-alkyl;
- R_2 is independently selected from a halogen, -CF_2H, -CF_3, -OCF_2H, -OCF_3, substituted or unsubstituted C5-C18 carboxyl, substituted or unsubstituted C5-C18 alkane, substituted or

unsubstituted C5-C18 alkene, substituted or unsubstituted C5-C18 cyclic alkene, substituted or unsubstituted C5-C18 alkyne, substituted or unsubstituted C5-C18 ketone, substituted or unsubstituted C5-C18 aldehyde, substituted or unsubstituted C5-C18 ether, substituted or unsubstituted C5-C18 ester, substituted or unsubstituted C5-C18 amine, substituted or unsubstituted C5-C18 amide, substituted or unsubstituted C5-C18 alkyl-amide, monocyclic or polycyclic arene, heteroarene, phenol, and benzoic acid;

- R_3 and R_4 may be the same or different, and are selected from H, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8-cycloalkyl, substituted or unsubstituted pyridine, substituted or unsubstituted C2-C10 carboxyl, substituted or unsubstituted C2-C10 alkene, substituted or unsubstituted C2-C10 alkyne, substituted or unsubstituted C2-C10 ketone, substituted or unsubstituted C2-C10 aldehyde, substituted or unsubstituted C2-C10 ether, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C2-C10 amine, substituted or unsubstituted C2-C10 amide, substituted or unsubstituted C2-C10 alkyl-amide, substituted or unsubstituted phenol, and benzoic acid;
- R_5 is selected from H, $-CF_3$, $-OCF_3$, $-OCHF_2$, $-NO_2$, and -CN;
- L_1 is independently selected from: $-OR_{2a}-$, $-SR_{2a}-$, $-NR_{2a}-$, $-NR_{2a}C(O)R_{2a}-$, $-OC(O)R_{2a}-$, $-C(O)OR_{2a}-$, $-SO_2R_{2a}$, $-S(O)R_{2a}-$, $-NR_{1a}C(O)-$, $-C(O)NR_{2a}-$, $-NR_{2a}S(O)_2-$, $S(O)_2NR_{2a}-$, $-OC(O)NR_{2a}-$, $-NR_{2a}C(O)OR_{2a}-$, $-NR_{1a}C(O)NR_{2a}-$, $-CR_{2a}=CR_{2a}-$ and -CC-, $-CH_2R_{2a}-$;
    - R_{2a} is independently selected from: H, alkyl, alkenyl, alkynyl, cycloalkyl heterocycloalkyl, heteroaryl or phenyl is optionally substituted where chemically allowed by from 1-4 groups independently selected from oxo, C_1-C_6-alkyl, C_2-C_6-

alkynyl, C_2-C_6-alkenyl, C_1-C_6-haloalkyl; OR_a, NR_yR_b, SR_y, $C(O)OR_y$, $C(O)NR_yR_b$, halo, cyano, nitro, $C(O)R_y$, $S(O)_2OR_y$;

- wherein R_y is independently at each occurrence selected from: H and C_1-C_6-alkyl; and R_b is independently at each occurrence selected from: H and C_1-C_6-alkyl, $C(O)C_1$-C_6-alkyl and $S(O)_2$-C_1-C_6-alkyl;


and X^- selected from a suitable anion to form a pharmaceutically acceptable salt.

2. The compound of claim 1, wherein X^- is selected from the group consisting of acetate, benzenesulfonate, benzoate, besylate, bitartrate, bromide, bamsylate, chloride, citrate, decanoate, edetate, esylate, fumarate, gluceptate, hexanoate, iodide, isethionate, lactate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, octanoate, oleate, pamoate, pantothenate, phosphate, propionate, salicylate, stearate, succinate, sulfate, tartrate, teoclate, and tosylate.


3. The compound of any preceding claim, wherein X^- is selected from the group consisting of Cl^-, Br^-, I^-, and $MeSO_3^-$.

4. The compound of any one of claims 1-3, wherein R_5 is CF_3.


5. The compound of claim 1, having a structure selected from the group consisting of:




,




,


O
Cl
O
O
N
H
O
O
N
N
O
Cl⁻
P+


,


O
Cl
O
O
N
H
O
O
N
N
O
Cl⁻
P+

,



O
Cl
O
O
N
H
O
O
N
N
O
Cl⁻
P+

,


O
Cl
O
O
N
H
O
O
N
H
N
Cl⁻
P+


,


and



O
Cl
O
O
N
H
O
O
H
N
N
O
Cl⁻
P+


.


6. The compound of claim 1, having a structure selected from the group consisting of:






















































































,




,





,





,



,



,


,



,



,





,

,



,




,




,




,




,




,



,




,




.


7. The compound of claim 1, having a structure selected from the group consisting of:




,




,



,



, and



8. The compound of claim 1, wherein R_5 is CF_3 at each occurrence.

9. The compound of claim 1, wherein R_5 is H at each occurrence.

10. A pharmaceutical composition comprising the compound of any one of claims 1-9, and a pharmaceutically acceptable carrier

11. The pharmaceutical composition of claim 10, wherein the carrier is selected from the group consisting of a sugar, lactose, glucose, sucrose, a starch, corn starch, potato starch, cellulose, sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, tragacanth, malt, gelatin, talc, cocoa butter, a glycol, propylene glycol, a polyols, glycerin, sorbitol, mannitol, polyethylene glycol, an ester, ethyl oleate, ethyl laurate, agar, a buffering agent, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, a phosphate buffer solution.

12. The pharmaceutical composition of claim 10, wherein the excipient is selected from the group consisting of lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, cyclodextrins, crystalline cellulose, silicic acid.

13. Use of a pharmaceutical composition comprising the compound of any one of claims 1-9 in the manufacture of a medicament for treating or preventing tumor recurrence and/or metastasis, wherein the pharmaceutical composition is suitable for being administered to a patient at risk of tumor recurrence and/or metastasis.

14. The use of claim 13, wherein the pharmaceutical composition is suitable for being administered at least one of prior to a cancer treatment, with a cancer treatment, and following a cancer treatment.

15. Use of a pharmaceutical composition comprising the compound of any one of claims 1-9 in the manufacture of a medicament for inhibiting the propagation of cancer stem cells in a patient.

16. The use of claim 15, wherein the pharmaceutical composition is suitable for being administered at least one of prior to a cancer treatment, with a cancer treatment, and following a cancer treatment.

17. Use of a pharmaceutical composition comprising the compound of any one of claims 1-9 in the manufacture of a medicament for treating cancer, wherein the pharmaceutical composition is suitable for being administered to a person having cancer.

18. The use of claim 17, wherein the pharmaceutical composition is suitable for being administered at least one of prior to a cancer treatment, with a cancer treatment, and following a cancer treatment.